Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Fulgent Genetics awarded CDC genomic sequencing contract for SARS-CoV-2 samples » 16:12
03/15/21
03/15
16:12
03/15/21
16:12
FLGT

Fulgent Genetics

$104.14 /

+8.58 (+8.98%)

Fulgent Genetics…

Fulgent Genetics announced that the U.S. Centers for Disease Control and Prevention, or CDC, has awarded the company a contract to provide genomic sequencing of samples of SARS-CoV-2 on an ongoing basis, leveraging the company's next generation sequencing, or NGS, capabilities. Under the agreement, Fulgent Genetics will sequence the genomes of random samples that have tested positive for SARS-CoV-2, the virus that causes COVID-19. Fulgent will leverage its NGS platform and provide sequencing data to the CDC as part of their initiative to conduct a large-scale genomic survey of the virus using random samples from across the United States. Ultimately, the CDC believes this large-scale genomic survey of the virus can provide important baseline information for national and state-level virus surveillance, help define changes in transmission, help to identify unusual or emerging variants, and ultimately improve the public health response to the virus. Fulgent said it was selected as a partner due to its access to samples, laboratory capabilities for processing and sequencing of these samples, ability to manage the significant amount of data collected, and ability to deliver data to the CDC under the strict specifications they require.

ShowHide Related Items >><<
FLGT Fulgent Genetics
$104.14 /

+8.58 (+8.98%)

FLGT Fulgent Genetics
$104.14 /

+8.58 (+8.98%)

03/05/21 Piper Sandler
Fulgent Genetics price target raised to $140 from $135 at Piper Sandler
02/03/21 Piper Sandler
Fulgent Genetics price target raised to $135 from $100 at Piper Sandler
02/01/21 Oppenheimer
Fulgent Genetics price target raised to $130 from $75 at Oppenheimer
02/01/21 Oppenheimer
Invitae downgraded to Perform on valuation at Oppenheimer
FLGT Fulgent Genetics
$104.14 /

+8.58 (+8.98%)

FLGT Fulgent Genetics
$104.14 /

+8.58 (+8.98%)

Over a month ago
Hot Stocks
Quidel slips, drags on peers as demand for testing 'softens significantly' » 14:46
03/10/21
03/10
14:46
03/10/21
14:46
QDEL

Quidel

$130.00 /

-25.51 (-16.40%)

, QGEN

Qiagen

$45.74 /

-1.915 (-4.02%)

, FLGT

Fulgent Genetics

$97.95 /

-12.01 (-10.92%)

, GNMK

GenMark

$16.62 /

-3.3 (-16.57%)

, PKI

PerkinElmer

$120.59 /

-5.41 (-4.29%)

, BDX

Becton Dickinson

$236.90 /

-6.13 (-2.52%)

, HOLX

Hologic

$68.01 /

-3.89 (-5.41%)

Shares of Quidel (QDEL)…

Shares of Quidel (QDEL) are under pressure on Wednesday after the company said demand for testing was down 30%-40% quarter-to-date versus the fourth quarter and that it sees quarterly revenue of "at least" $450M, with consensus estimates at roughly $755M. The guidance also sent shares of several peers, including Qiagen (QGEN) and Fulgent Genetics (FLGT), into negative territory. DEMAND DOWN: During Barclays' Global Health Virtual Conference, Quidel said that testing in February and March has "softened significantly," with demand for testing down 30%-40% quarter-to-date versus the fourth quarter. The company also noted that it sees revenue of "at least" $450M for the quarter, with consensus at $755.07M. For the current fiscal year, Quidel sees revenue of roughly $2.5B, with consensus at $2.87B. PRICE ACTION: In afternoon trading, shares of Quidel have dropped over 16% to $130.75. Also lower, Qiagen has slipped almost 4% to $45.84, Fulgent Genetics has plunged over 12% to $96.09, GenMark (GNMK) has slid more than 18% to $16.31, PerkinElmer (PKI) has slipped over 4% to $120.57, Becton Dickinson (BDX) has slid about 2% to $237.50, and Opko Health (OPKO) and Hologic (HOLX) have dropped about 5% apiece to $4.31 and $68.47, respectively.

ShowHide Related Items >><<
QGEN Qiagen
$45.74 /

-1.915 (-4.02%)

QDEL Quidel
$130.00 /

-25.51 (-16.40%)

PKI PerkinElmer
$120.59 /

-5.41 (-4.29%)

HOLX Hologic
$68.01 /

-3.89 (-5.41%)

GNMK GenMark
$16.62 /

-3.3 (-16.57%)

FLGT Fulgent Genetics
$97.95 /

-12.01 (-10.92%)

BDX Becton Dickinson
$236.90 /

-6.13 (-2.52%)

QDEL Quidel
$130.00 /

-25.51 (-16.40%)

02/19/21 JPMorgan
Quidel price target lowered to $170 from $175 at JPMorgan
02/19/21 Piper Sandler
Quidel should be bought on QuickVue OTC delay, says Piper Sandler
02/09/21 William Blair
Quidel, Qiagen merger would not make sense, says William Blair
02/09/21 Wells Fargo
Qiagen shares should be sold on latest merger talk, says Wells Fargo
QGEN Qiagen
$45.74 /

-1.915 (-4.02%)

02/19/21 Berenberg
Qiagen price target raised to EUR 56 from EUR 52 at Berenberg
02/09/21 Citi
Merger with Qiagen would benefit Quidel, says Citi
FLGT Fulgent Genetics
$97.95 /

-12.01 (-10.92%)

03/05/21 Piper Sandler
Fulgent Genetics price target raised to $140 from $135 at Piper Sandler
02/03/21 Piper Sandler
Fulgent Genetics price target raised to $135 from $100 at Piper Sandler
02/01/21 Oppenheimer
Fulgent Genetics price target raised to $130 from $75 at Oppenheimer
02/01/21 Oppenheimer
Invitae downgraded to Perform on valuation at Oppenheimer
GNMK GenMark
$16.62 /

-3.3 (-16.57%)

02/16/21 Canaccord
GenMark price target raised to $24 from $22 at Canaccord
10/09/20 Canaccord
Execution positions GenMark for long-term success, says Canaccord
08/28/20 Canaccord
Hospital service channel shares weakness a buying opportunity, says Canaccord
08/05/20 Canaccord
GenMark price target raised to $22 from $20 at Canaccord
PKI PerkinElmer
$120.59 /

-5.41 (-4.29%)

02/03/21 Citi
PerkinElmer price target raised to $155 from $150 at Citi
01/07/21 Piper Sandler
Oxford Immunotec downgraded to Neutral from Overweight at Piper Sandler
01/07/21 Wells Fargo
PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
01/07/21 Wells Fargo
PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
BDX Becton Dickinson
$236.90 /

-6.13 (-2.52%)

02/12/21 Wells Fargo
Wells Fargo sees only 'small chance' of positive FDA panel for Becton
02/05/21 Citi
Becton Dickinson price target raised to $280 from $273 at Citi
02/04/21 Piper Sandler
Becton Dickinson price target raised to $280 from $275 at Piper Sandler
12/15/20
Fly Intel: Top five analyst downgrades
HOLX Hologic
$68.01 /

-3.89 (-5.41%)

02/22/21 BTIG
Hologic price target raised to $91 from $84 at BTIG
01/28/21 Wells Fargo
Hologic price target raised to $95 from $90 at Wells Fargo
12/08/20 Argus
Hologic price target raised to $100 from $85 at Argus
11/20/20
Fly Intel: Top five analyst downgrades
QGEN Qiagen
$45.74 /

-1.915 (-4.02%)

QDEL Quidel
$130.00 /

-25.51 (-16.40%)

PKI PerkinElmer
$120.59 /

-5.41 (-4.29%)

HOLX Hologic
$68.01 /

-3.89 (-5.41%)

GNMK GenMark
$16.62 /

-3.3 (-16.57%)

FLGT Fulgent Genetics
$97.95 /

-12.01 (-10.92%)

BDX Becton Dickinson
$236.90 /

-6.13 (-2.52%)

  • 21
    May
  • 07
    May
QDEL Quidel
$130.00 /

-25.51 (-16.40%)

HOLX Hologic
$68.01 /

-3.89 (-5.41%)

GNMK GenMark
$16.62 /

-3.3 (-16.57%)

BDX Becton Dickinson
$236.90 /

-6.13 (-2.52%)

QGEN Qiagen
$45.74 /

-1.915 (-4.02%)

QDEL Quidel
$130.00 /

-25.51 (-16.40%)

PKI PerkinElmer
$120.59 /

-5.41 (-4.29%)

HOLX Hologic
$68.01 /

-3.89 (-5.41%)

GNMK GenMark
$16.62 /

-3.3 (-16.57%)

FLGT Fulgent Genetics
$97.95 /

-12.01 (-10.92%)

BDX Becton Dickinson
$236.90 /

-6.13 (-2.52%)

QGEN Qiagen
$45.74 /

-1.915 (-4.02%)

PKI PerkinElmer
$120.59 /

-5.41 (-4.29%)

HOLX Hologic
$68.01 /

-3.89 (-5.41%)

Recommendations
Fulgent Genetics price target raised to $140 from $135 at Piper Sandler » 05:06
03/05/21
03/05
05:06
03/05/21
05:06
FLGT

Fulgent Genetics

$85.08 /

-7.3 (-7.90%)

Piper Sandler analyst…

Piper Sandler analyst Steven Mah raised the firm's price target on Fulgent Genetics to $140 from $135 and keeps an Overweight rating on the shares post the Q4 results. The analyst believes management is being conservative on guidance and notes multiple sources of upside that are not baked into the guide"

ShowHide Related Items >><<
FLGT Fulgent Genetics
$85.08 /

-7.3 (-7.90%)

FLGT Fulgent Genetics
$85.08 /

-7.3 (-7.90%)

02/03/21 Piper Sandler
Fulgent Genetics price target raised to $135 from $100 at Piper Sandler
02/01/21 Oppenheimer
Fulgent Genetics price target raised to $130 from $75 at Oppenheimer
02/01/21 Oppenheimer
Invitae downgraded to Perform on valuation at Oppenheimer
01/08/21 Credit Suisse
Fulgent Genetics downgraded to Underperform from Neutral at Credit Suisse
FLGT Fulgent Genetics
$85.08 /

-7.3 (-7.90%)

FLGT Fulgent Genetics
$85.08 /

-7.3 (-7.90%)

FLGT Fulgent Genetics
$85.08 /

-7.3 (-7.90%)

Earnings
Fulgent Genetics sees FY21 EPS $12.50, consensus $11.55 » 16:15
03/04/21
03/04
16:15
03/04/21
16:15
FLGT

Fulgent Genetics

$85.08 /

-7.3 (-7.90%)

Sees FY21 revenue $800M,…

Sees FY21 revenue $800M, consensus $600.24M. Of the $800M, the company anticipates $70M in revenue from NGS testing, representing growth of 92% year-over-year.

ShowHide Related Items >><<
FLGT Fulgent Genetics
$85.08 /

-7.3 (-7.90%)

FLGT Fulgent Genetics
$85.08 /

-7.3 (-7.90%)

02/03/21 Piper Sandler
Fulgent Genetics price target raised to $135 from $100 at Piper Sandler
02/01/21 Oppenheimer
Fulgent Genetics price target raised to $130 from $75 at Oppenheimer
02/01/21 Oppenheimer
Invitae downgraded to Perform on valuation at Oppenheimer
01/08/21 Credit Suisse
Fulgent Genetics downgraded to Underperform from Neutral at Credit Suisse
FLGT Fulgent Genetics
$85.08 /

-7.3 (-7.90%)

FLGT Fulgent Genetics
$85.08 /

-7.3 (-7.90%)

FLGT Fulgent Genetics
$85.08 /

-7.3 (-7.90%)

Earnings
Fulgent Genetics reports Q4 EPS $6.20, consensus $4.05 » 16:13
03/04/21
03/04
16:13
03/04/21
16:13
FLGT

Fulgent Genetics

$85.08 /

-7.3 (-7.90%)

Reports Q4 revenue…

Reports Q4 revenue $294.98M, consensus $199.44M. Ming Hsieh, chairman and CEO, said, "Our record fourth quarter results capped off a transformational year for Fulgent Genetics. While we did not envision 2020 to unfold in the way that it did, I am proud of our team for supporting the pivot of our business to rapidly scale to become one of the top providers of COVID-19 testing in the country. The results we achieved were possible because of our differentiated technology platform built over the ten years since our founding. While the majority of our business this year was from COVID-19 testing, we believe we have laid a very strong foundation for continued growth in the years ahead. This year we made inroads with numerous new customers, established new reimbursement agreements, expanded our capacity and commercial capabilities, and have grown our direct-to-consumer genetic testing platform, Picture Genetics. We have also begun utilizing our NGS based COVID testing capabilities to aid in identification and screening of potential new strains and mutations of the virus. And finally, we have taken a novel approach to licensing our lab management software solutions and are offering a new COVID vaccine management software platform, which will continue to aid in recovery from the pandemic. I believe we are extremely well positioned in the years ahead as vaccine rollout continues and our lives return to a state of normalcy."

ShowHide Related Items >><<
FLGT Fulgent Genetics
$85.08 /

-7.3 (-7.90%)

FLGT Fulgent Genetics
$85.08 /

-7.3 (-7.90%)

02/03/21 Piper Sandler
Fulgent Genetics price target raised to $135 from $100 at Piper Sandler
02/01/21 Oppenheimer
Fulgent Genetics price target raised to $130 from $75 at Oppenheimer
02/01/21 Oppenheimer
Invitae downgraded to Perform on valuation at Oppenheimer
01/08/21 Credit Suisse
Fulgent Genetics downgraded to Underperform from Neutral at Credit Suisse
FLGT Fulgent Genetics
$85.08 /

-7.3 (-7.90%)

FLGT Fulgent Genetics
$85.08 /

-7.3 (-7.90%)

FLGT Fulgent Genetics
$85.08 /

-7.3 (-7.90%)

Hot Stocks
Fulgent Genetics, BioIQ partner on COVID-19 testing programs » 10:02
02/16/21
02/16
10:02
02/16/21
10:02
FLGT

Fulgent Genetics

$156.00 /

-5.02 (-3.12%)

BioIQ announces a…

BioIQ announces a partnership with Fulgent Genetics to offer viral genome sequencing capable of identifying various variants of the COVID-19 virus. Fulgent Genetics' full viral genome sequencing is a new and rapidly evolving tool that better characterizes COVID-19 infections and the consequences of new variants in the population. The partnership makes it possible for BioIQ employer, government, and health plan customers to leverage Fulgent Genetics' testing solution to inform testing regimens, clinical treatment protocols and vaccination strategies pursuant to the identified COVID-19 variant. Local public health agencies can similarly leverage the testing solution in ongoing population infection surveillance programs with BioIQ.

ShowHide Related Items >><<
FLGT Fulgent Genetics
$156.00 /

-5.02 (-3.12%)

FLGT Fulgent Genetics
$156.00 /

-5.02 (-3.12%)

02/03/21 Piper Sandler
Fulgent Genetics price target raised to $135 from $100 at Piper Sandler
02/01/21 Oppenheimer
Fulgent Genetics price target raised to $130 from $75 at Oppenheimer
02/01/21 Oppenheimer
Invitae downgraded to Perform on valuation at Oppenheimer
01/08/21 Credit Suisse
Fulgent Genetics downgraded to Underperform from Neutral at Credit Suisse
FLGT Fulgent Genetics
$156.00 /

-5.02 (-3.12%)

FLGT Fulgent Genetics
$156.00 /

-5.02 (-3.12%)

FLGT Fulgent Genetics
$156.00 /

-5.02 (-3.12%)

FLGT Fulgent Genetics
$156.00 /

-5.02 (-3.12%)

Recommendations
Fulgent Genetics price target raised to $135 from $100 at Piper Sandler » 05:11
02/03/21
02/03
05:11
02/03/21
05:11
FLGT

Fulgent Genetics

$112.82 /

-25.63 (-18.51%)

Piper Sandler analyst…

Piper Sandler analyst Steven Mah raised the firm's price target on Fulgent Genetics to $135 from $100 and keeps an Overweight rating on the shares. Based on publicly available information from California, channel checks imply Fulgent performed 2M COVID-19 tests in California in Q4, Mah tells investors in a research note. This beats his estimate of 1.49M total COVID-19 tests for the entire U.S.. The checks also imply Fulgent is on track to beat the Q1 estimate as well, Mah tells investors in a research note. The analyst now has increased confidence in Fulgent's testing.

ShowHide Related Items >><<
FLGT Fulgent Genetics
$112.82 /

-25.63 (-18.51%)

FLGT Fulgent Genetics
$112.82 /

-25.63 (-18.51%)

02/01/21 Oppenheimer
Fulgent Genetics price target raised to $130 from $75 at Oppenheimer
02/01/21 Oppenheimer
Invitae downgraded to Perform on valuation at Oppenheimer
01/08/21 Credit Suisse
Fulgent Genetics downgraded to Underperform from Neutral at Credit Suisse
11/24/20
Fly Intel: Top five analyst downgrades
FLGT Fulgent Genetics
$112.82 /

-25.63 (-18.51%)

FLGT Fulgent Genetics
$112.82 /

-25.63 (-18.51%)

FLGT Fulgent Genetics
$112.82 /

-25.63 (-18.51%)

FLGT Fulgent Genetics
$112.82 /

-25.63 (-18.51%)

Recommendations
Fulgent Genetics price target raised to $130 from $75 at Oppenheimer » 08:34
02/01/21
02/01
08:34
02/01/21
08:34
FLGT

Fulgent Genetics

$110.24 /

+17.745 (+19.19%)

Oppenheimer analyst Kevin…

Oppenheimer analyst Kevin DeGeeter raised the firm's price target on Fulgent Genetics to $130 from $75 and keeps an Outperform rating on the shares. The analyst notes that since December, Fulgent has increased share in California from 10% to 17%, while consistently generating turnaround time at or below statewide median. He looks to continue accumulating Fulgent into recent strength and into expected early March Q4 financial results update.

ShowHide Related Items >><<
FLGT Fulgent Genetics
$110.24 /

+17.745 (+19.19%)

FLGT Fulgent Genetics
$110.24 /

+17.745 (+19.19%)

02/01/21 Oppenheimer
Invitae downgraded to Perform on valuation at Oppenheimer
01/08/21 Credit Suisse
Fulgent Genetics downgraded to Underperform from Neutral at Credit Suisse
11/24/20
Fly Intel: Top five analyst downgrades
11/24/20 BTIG
Fulgent Genetics downgraded to Neutral from Buy at BTIG
FLGT Fulgent Genetics
$110.24 /

+17.745 (+19.19%)

FLGT Fulgent Genetics
$110.24 /

+17.745 (+19.19%)

FLGT Fulgent Genetics
$110.24 /

+17.745 (+19.19%)

FLGT Fulgent Genetics
$110.24 /

+17.745 (+19.19%)

Downgrade
Invitae downgraded to Perform on valuation at Oppenheimer » 07:19
02/01/21
02/01
07:19
02/01/21
07:19
NVTA

Invitae

$49.56 /

-1.34 (-2.63%)

, EXAS

Exact Sciences

$137.51 /

-2.04 (-1.46%)

, FLGT

Fulgent Genetics

$110.24 /

+17.745 (+19.19%)

As previously reported,…

As previously reported, Oppenheimer analyst Kevin DeGeeter downgraded Invitae (NVTA) to Perform from Outperform. The analyst notes that the shares recently reaching his prior price target of $51. He also cites ambiguity regarding synergies between ArcherDx and Invitae's franchises in hereditary cancer and women's health; and preference for Invitae to provide greater financial transparency on impact from M&A and growth initiatives. While DeGeeter views 2021 guidance for revenues of $450M-plus as potentially conservative, he believes opportunities for further multiple expansion may be limited contributing to increased risk of underperformance for Invitae shares. The analyst views larger cap names such as Exact Sciences (EXAS) or special situations such as Fulgent Genetics (FLGT) as more appropriate for investors putting new money into the sector.

ShowHide Related Items >><<
NVTA Invitae
$49.56 /

-1.34 (-2.63%)

FLGT Fulgent Genetics
$110.24 /

+17.745 (+19.19%)

EXAS Exact Sciences
$137.51 /

-2.04 (-1.46%)

NVTA Invitae
$49.56 /

-1.34 (-2.63%)

02/01/21 Oppenheimer
Invitae downgraded to Perform from Outperform at Oppenheimer
11/06/20 Ladenburg
Invitae downgraded to Neutral on valuation at Ladenburg
11/06/20 Ladenburg
Invitae downgraded to Neutral from Buy at Ladenburg
11/03/20 SVB Leerink
Invitae price target raised to $44 from $34 at SVB Leerink
EXAS Exact Sciences
$137.51 /

-2.04 (-1.46%)

01/27/21 Truist
Exact Sciences initiated with a Buy at Truist
01/12/21 Stifel
Renalytix AI, Exact Sciences may benefit from final MCIT rule, says Stifel
01/12/21 Canaccord
Exact Sciences price target raised to $165 from $160 at Canaccord
01/12/21 Oppenheimer
Exact Sciences price target raised to $161 from $153 at Oppenheimer
FLGT Fulgent Genetics
$110.24 /

+17.745 (+19.19%)

01/08/21 Credit Suisse
Fulgent Genetics downgraded to Underperform from Neutral at Credit Suisse
11/24/20
Fly Intel: Top five analyst downgrades
11/24/20 BTIG
Fulgent Genetics downgraded to Neutral from Buy at BTIG
11/10/20 Piper Sandler
Fulgent Genetics price target raised to $100 from $73 at Piper Sandler
NVTA Invitae
$49.56 /

-1.34 (-2.63%)

FLGT Fulgent Genetics
$110.24 /

+17.745 (+19.19%)

EXAS Exact Sciences
$137.51 /

-2.04 (-1.46%)

  • 22
    Jan
  • 02
    Apr
FLGT Fulgent Genetics
$110.24 /

+17.745 (+19.19%)

NVTA Invitae
$49.56 /

-1.34 (-2.63%)

FLGT Fulgent Genetics
$110.24 /

+17.745 (+19.19%)

EXAS Exact Sciences
$137.51 /

-2.04 (-1.46%)

NVTA Invitae
$49.56 /

-1.34 (-2.63%)

FLGT Fulgent Genetics
$110.24 /

+17.745 (+19.19%)

EXAS Exact Sciences
$137.51 /

-2.04 (-1.46%)

Over a quarter ago
On The Fly
Fly Intel: Wall Street's top stories for Friday » 16:14
01/08/21
01/08
16:14
01/08/21
16:14
MU

Micron

$77.29 /

-1.79 (-2.26%)

, BA

Boeing

$209.70 /

-3.05 (-1.43%)

, PFE

Pfizer

$37.17 /

+0.115 (+0.31%)

, BNTX

BioNTech

$100.46 /

+6.8 (+7.26%)

, MRNA

Moderna

$112.79 /

-2.38 (-2.07%)

, SRPT

Sarepta

$82.53 /

-86.355 (-51.13%)

, DB

Deutsche Bank

$11.67 /

-0.015 (-0.13%)

, CMRX

Chimerix

$8.40 /

+3.43 (+69.01%)

, ACIA

Acacia Communications

$79.37 /

+6.87 (+9.48%)

, CSCO

Cisco

$45.03 /

+0.08 (+0.18%)

, BNGO

Bionano Genomics

$4.66 /

-0.32 (-6.43%)

, FLGT

Fulgent Genetics

$63.38 /

-7.52 (-10.61%)

Equity futures took the…

ShowHide Related Items >><<
SRPT Sarepta
$82.53 /

-86.355 (-51.13%)

PFE Pfizer
$37.17 /

+0.115 (+0.31%)

MU Micron
$77.29 /

-1.79 (-2.26%)

MRNA Moderna
$112.79 /

-2.38 (-2.07%)

FLGT Fulgent Genetics
$63.38 /

-7.52 (-10.61%)

DB Deutsche Bank
$11.67 /

-0.015 (-0.13%)

CSCO Cisco
$45.03 /

+0.08 (+0.18%)

CMRX Chimerix
$8.40 /

+3.43 (+69.01%)

BNTX BioNTech
$100.46 /

+6.8 (+7.26%)

BNGO Bionano Genomics
$4.66 /

-0.32 (-6.43%)

BA Boeing
$209.70 /

-3.05 (-1.43%)

ACIA Acacia Communications
$79.37 /

+6.87 (+9.48%)

MU Micron
$77.29 /

-1.79 (-2.26%)

01/08/21 JPMorgan
Micron price target raised to $100 from $85 at JPMorgan
01/08/21 Wells Fargo
Wells Fargo says Micron remains 2021 Top Pick after Q1 report
01/08/21 Evercore ISI
Micron price target raised to $105 from $90 at Evercore ISI
01/08/21 Wedbush
Micron price target raised to $88 from $82 at Wedbush
BA Boeing
$209.70 /

-3.05 (-1.43%)

01/04/21
Fly Intel: Top five analyst downgrades
01/04/21 Baird
Boeing elevated to Fresh Pick at Baird
01/04/21 Bernstein
Bernstein downgrades Boeing to Underperform on worsening 787 outlook
01/04/21 Bernstein
Boeing downgraded to Underperform from Market Perform at Bernstein
PFE Pfizer
$37.17 /

+0.115 (+0.31%)

01/05/21 Argus
Viatris initiated with a Hold at Argus
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
12/29/20 Citi
Citi boosts Myovant target to $30 on 'smart deal' with Pfizer
12/29/20 Citi
Arcturus selloff brings 'very good' buying opportunity, says Citi
BNTX BioNTech
$100.46 /

+6.8 (+7.26%)

12/22/20 Roth Capital
Translate Bio price target raised to $37 from $30 at Roth Capital
12/15/20 Jefferies
Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play'
12/14/20 Citi
Arcturus Therapeutics price target raised to $133 from $62 at Citi
MRNA Moderna
$112.79 /

-2.38 (-2.07%)

01/06/21 Piper Sandler
Moderna price target raised to $170 after EU vaccine approval at Piper Sandler
01/04/21 Piper Sandler
Moderna shares warrant 'fresh look' after 41% pullback, says Piper Sandler
SRPT Sarepta
$82.53 /

-86.355 (-51.13%)

01/08/21 Chardan
Solid Biosciences selloff on Sarepta news a buying opportunity, says Chardan
01/08/21 JPMorgan
Sarepta downgraded to Underweight from Overweight at JPMorgan
01/08/21 Baird
Sarepta price target lowered to $110 from $223 at Baird
01/08/21 Cowen
Sarepta price target lowered to $114 from $213 at Cowen
DB Deutsche Bank
$11.67 /

-0.015 (-0.13%)

12/10/20 RBC Capital
Deutsche Bank price target raised to EUR 10 from EUR 9 at RBC Capital
12/10/20 JPMorgan
Deutsche Bank price target raised to EUR 8.50 from EUR 7.50 at JPMorgan
10/30/20 Barclays
Deutsche Bank price target raised to EUR 6 from EUR 5 at Barclays
10/29/20 JPMorgan
Deutsche Bank price target raised to EUR 7.50 from EUR 7 at JPMorgan
CMRX Chimerix
$8.40 /

+3.43 (+69.01%)

05/21/20 JonesTrading
Chimerix initiated with a Buy at JonesTrading
ACIA Acacia Communications
$79.37 /

+6.87 (+9.48%)

01/08/21 Craig-Hallum
Acacia upgraded to Buy at Craig-Hallum after Cisco deal termination
01/08/21 Craig-Hallum
Acacia Communications upgraded to Buy from Hold at Craig-Hallum
CSCO Cisco
$45.03 /

+0.08 (+0.18%)

11/13/20 New Street
Cisco upgraded to Buy from Neutral at New Street
11/13/20 Morgan Stanley
Cisco 'just fine' after 'better than feared' Q1 report, says Morgan Stanley
11/13/20 Citi
Cisco price target raised to $45 from $43 at Citi
BNGO Bionano Genomics
$4.66 /

-0.32 (-6.43%)

12/04/20 Roth Capital
Bionano Genomics downgraded to Neutral from Buy at Roth Capital
12/04/20 Roth Capital
Bionano Genomics downgraded to Neutral from Buy at Roth Capital
09/24/20 Ladenburg
Bionano Genomics initiated with a Buy at Ladenburg
04/08/20 Oppenheimer
Oppenheimer bullish on Bionano Genomics, initiates with an Outperform
FLGT Fulgent Genetics
$63.38 /

-7.52 (-10.61%)

01/08/21 Credit Suisse
Fulgent Genetics downgraded to Underperform from Neutral at Credit Suisse
11/24/20
Fly Intel: Top five analyst downgrades
11/24/20 BTIG
Fulgent Genetics downgraded to Neutral from Buy at BTIG
11/10/20 Piper Sandler
Fulgent Genetics price target raised to $100 from $73 at Piper Sandler
SRPT Sarepta
$82.53 /

-86.355 (-51.13%)

PFE Pfizer
$37.17 /

+0.115 (+0.31%)

MU Micron
$77.29 /

-1.79 (-2.26%)

MRNA Moderna
$112.79 /

-2.38 (-2.07%)

FLGT Fulgent Genetics
$63.38 /

-7.52 (-10.61%)

DB Deutsche Bank
$11.67 /

-0.015 (-0.13%)

CSCO Cisco
$45.03 /

+0.08 (+0.18%)

CMRX Chimerix
$8.40 /

+3.43 (+69.01%)

BNTX BioNTech
$100.46 /

+6.8 (+7.26%)

BNGO Bionano Genomics
$4.66 /

-0.32 (-6.43%)

BA Boeing
$209.70 /

-3.05 (-1.43%)

ACIA Acacia Communications
$79.37 /

+6.87 (+9.48%)

  • 08
    Jan
  • 23
    Jul
  • 19
    May
  • 12
    Feb
  • 06
    Feb
PFE Pfizer
$37.17 /

+0.115 (+0.31%)

MU Micron
$77.29 /

-1.79 (-2.26%)

MRNA Moderna
$112.79 /

-2.38 (-2.07%)

FLGT Fulgent Genetics
$63.38 /

-7.52 (-10.61%)

DB Deutsche Bank
$11.67 /

-0.015 (-0.13%)

CSCO Cisco
$45.03 /

+0.08 (+0.18%)

BNTX BioNTech
$100.46 /

+6.8 (+7.26%)

BA Boeing
$209.70 /

-3.05 (-1.43%)

ACIA Acacia Communications
$79.37 /

+6.87 (+9.48%)

SRPT Sarepta
$82.53 /

-86.355 (-51.13%)

PFE Pfizer
$37.17 /

+0.115 (+0.31%)

MU Micron
$77.29 /

-1.79 (-2.26%)

MRNA Moderna
$112.79 /

-2.38 (-2.07%)

FLGT Fulgent Genetics
$63.38 /

-7.52 (-10.61%)

DB Deutsche Bank
$11.67 /

-0.015 (-0.13%)

CSCO Cisco
$45.03 /

+0.08 (+0.18%)

CMRX Chimerix
$8.40 /

+3.43 (+69.01%)

BNTX BioNTech
$100.46 /

+6.8 (+7.26%)

BNGO Bionano Genomics
$4.66 /

-0.32 (-6.43%)

BA Boeing
$209.70 /

-3.05 (-1.43%)

ACIA Acacia Communications
$79.37 /

+6.87 (+9.48%)

PFE Pfizer
$37.17 /

+0.115 (+0.31%)

MU Micron
$77.29 /

-1.79 (-2.26%)

MRNA Moderna
$112.79 /

-2.38 (-2.07%)

FLGT Fulgent Genetics
$63.38 /

-7.52 (-10.61%)

DB Deutsche Bank
$11.67 /

-0.015 (-0.13%)

CSCO Cisco
$45.03 /

+0.08 (+0.18%)

BNTX BioNTech
$100.46 /

+6.8 (+7.26%)

BA Boeing
$209.70 /

-3.05 (-1.43%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.